// App-Quantinova.ai

[THU0240] : EARLY CLINICAL RESPONSE IS A BETTER PREDICTOR OF LONG-TERM REMISSION THAN BASELINE DISEASE CHARACTERISTICS FOLLOWING ADALIMUMAB TREATMENT IN PERIPHERAL SPONDYLOARTHRITIS

Researchers

Presenter

  • F. Van Den Bosch

Principal Investigators

  • P. Mease

  • J. Sieper

  • D. Baeten

  • N.A. Varothai

  • A.L. Pangan

  • I.H. Song

Medical Centers

  • Ghent University Hospital, Ghent, Belgium

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

  • Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

  • Swedish Medical Center and University of Washington School of Medicine, Seattle, WA

Locations

  • United States

  • Germany

  • Belgium

  • Netherlands

Companies

  • AbbVie Inc.

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Peripheral spondyloarthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Prolactin-secreting pituitary adenoma

Biomarkers

  • High sensitivity C-reactive protein

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved